Sample report / 2 pages / public sources only
Aducanumab, checked claim by claim, the way we would hand it to an investment committee. What held, what didn't, what nobody could establish, and the questions we would have put to the sponsor before a penny moved. Ten minutes to read.
Send me the 2 pagesInside the two pages
Why this asset? Famous enough that you know the headline. Public enough that every line can be checked. Close enough to a live deal that the method carries straight over to yours.